^
Association details:
| Biomarker: | BCR-ABL1 F317L |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug: | nilotinib (Bcr-abl inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Regimens for relapsed or refractory Ph-positive ALL…Bosutinib has minimal activity against F317L mutation. Nilotinib may be preferred over bosutinib in patients with F317L mutation.